Cardiovascular Project 2010-2013
1 - Acute Myocardial Infarction 30-day MortalityOrganization: Centers for Medicare & Medicaid Services (CMS)
Description: The measure estimates a hospital-level risk-standardized mortality rate (RSMR), defined as death from any cause within 30 days after the index admission date, for patients discharged from the hospital with a principal diagnosis of acute myocardial infarction.
Type: Outcome
2 - Heart Failure 30-day MortalityOrganization: Centers for Medicare & Medicaid Services (CMS)
Description: The measure estimates a hospital-level risk-standardized mortality rate (RSMR), defined as death from any cause within 30 days after the index admission date, for patients discharged from the hospital with a principal diagnosis of heart failure.
Type: Outcome
3 - 30-Day All-Cause Risk Standardized Readmission Rate Following Heart Failure Hospitalization (risk adjusted)Organization: Centers for Medicare & Medicaid Services (CMS)
Description: The measure estimates a hospital-level risk-standardized readmission rate (RSRR), defined as a readmission for any cause within 30 days after discharge of the index admission date, for patients discharged from the hospital with a principal diagnosis of heart failure.
Type: Outcome
4 - Hospital 30-day, all-cause, risk-standardized readmission rate (RSRR) following an ischemic stroke hospitalizationOrganization: Centers for Medicare & Medicaid Services (CMS)
Description: The measure estimates a hospital 30-day, risk-standardized readmission rate (RSRR), defined as readmission for any cause within 30 days after the date of discharge of the index admission for patients discharged from the hospital with a principal diagnosis of acute ischemic stroke.
Type: Outcome
5 - Hospital 30-day, all-cause, risk-standardized mortality rate (RSMR) following an ischemic stroke hospitalizationOrganization: Centers for Medicare & Medicaid Services (CMS)
Description: The measure estimates a hospital-level risk-standardized mortality rate (RSMR), defined as death from any cause within 30 days after the index admission date, for patients discharged from the hospital with a principal diagnosis of acute ischemic stroke.
Type: Outcome
6 - Chronic Stable Coronary Artery Disease: Blood Pressure ControlOrganization: American Medical Association-Physician Consortium for Performance Improvement
Description: Percentage of patients aged 18 years and older with a diagnosis of CAD with a blood pressure <140/90 mm Hg OR patients with a blood pressure =140/90 mm Hg and prescribed 2 or more anti-hypertensive medications during the most recent visit during the measurement period
Type: Process
7 - Chronic Stable Coronary Artery Disease: Symptom ManagementOrganization: American Medical Association-Physician Consortium for Performance Improvement
Description: Percentage patients aged 18 years and older with a diagnosis of CAD and with results of an evaluation of level of activity AND an evaluation of presence or absence of anginal symptoms, with appropriate management of anginal symptoms (evaluation of level of activity and symptoms includes no report of anginal symptoms OR evaluation of level of activity and symptoms includes report of anginal symptoms and a plan of care is documented to achieve control of anginal symptoms)
Type: Process
8 - Hypertension: Blood Pressure ControlOrganization: American Medical Association-Physician Consortium for Performance Improvement
Description: Percentage of patients aged 18 years and older with a diagnosis of hypertension with a blood pressure <140/90 mm Hg OR patients with a blood pressure =140/90 mm Hg and prescribed 2 or more anti-hypertensive medications during the most recent office visit during the measurement period
Type: Process
9 - Heart Failure: Post-Discharge Appointment for Heart Failure PatientsOrganization: American Medical Association-Physician Consortium for Performance Improvement
Description: Percentage of patients, regardless of age, discharged from an inpatient facility to ambulatory care or home health care with a principal discharge diagnosis of heart failure for whom a follow up appointment was scheduled and documented including location, date and time for a follow-up office visit, or home health visit (as specified)
Type: Process
10 - Assessment of Thromboembolic Risk FactorsOrganization: ACC/AHA Task Force on Performance Measures
Description: Patients with nonvalvular AF or atrial flutter in whom assessment of thromboembolic risk factors has been documented
Type: Process
11 - Chronic Anticoagulation TherapyOrganization: ACC/AHA Task Force on Performance Measures
Description: Prescription of warfarin for all patients with nonvalvular AF or atrial flutter at high risk for thromboembolism, according to risk stratification and 2006 guideline recommendations
Type: Process
12 - ACE/ARB Therapy at Discharge for ICD Implant Patients with Heart Failure and LVSDOrganization: American College of Cardiology Foundation (ACCF)
Description: Proportion of ICD implant patients with a diagnosis of heart failure and left ventricular systolic dysfunction who were prescribed ACE-I or ARB therapy at discharge.
Type: Process
13 - Beta Blocker at Discharge for ICD Implant Patients With a Previous MIOrganization: American College of Cardiology Foundation (ACCF)
Description: Proportion of ICD implant patients with a diagnosis of coronary artery disease and prior MI prescribed beta-blocker therapy on discharge.
Type: Process
14 - Beta Blocker at Discharge for ICD Implant Patients with Heart Failure and LVSDOrganization: American College of Cardiology Foundation (ACCF)
Description: Proportion of ICD implant patients with a diagnosis of heart failure and left ventricular systolic dysfunction (LVSD) who were prescribed beta-blocker therapy on discharge.
Type: Process
15 - Beta Blocker at Discharge for ICD Implant Patients with Heart Failure and LVSDOrganization: American College of Cardiology Foundation (ACCF)
Description: Proportion of ICD implant patients with a diagnosis of heart failure and left ventricular systolic dysfunction (LVSD) who were prescribed beta-blocker therapy on discharge.
Type: Process
16 - Prophylactic Antibiotics Prior to ICD ProcedureOrganization: American College of Cardiology Foundation (ACCF)
Description: Proportion of ICD implant patients that receive antibiotics within 1 hour (if fluoroquinolone or vancomycin, two hours) prior to procedure.
Type: Process
17 - Aspirin at discharge for patients with PCIOrganization: American College of Cardiology Foundation (ACCF)/ Society for Cardiovascular Angiography and Interventions (SCAI)
Description: Proportion of PCI patients with aspirin prescribed at discharge.
Type: Process
18 - Thienopyridine at discharge for patients with PCI (with stents)Organization: American College of Cardiology Foundation (ACCF)/ Society for Cardiovascular Angiography and Interventions (SCAI)
Description: Proportion of PCI patients with a stent implanted that had a thienopyridine prescribed at discharge.
Type: Process
19 - Thienopyridine at discharge for patients with PCI (with stents)Organization: American College of Cardiology Foundation (ACCF)/ Society for Cardiovascular Angiography and Interventions (SCAI)
Description: Proportion of PCI patients with a stent implanted that had a thienopyridine prescribed at discharge.
Type: Process
20 - Statins at discharge for patients with PCIOrganization: American College of Cardiology Foundation (ACCF)/ Society for Cardiovascular Angiography and Interventions (SCAI)
Description: PCI patients with a history of dyslipidemia who had a statin prescribed at discharge.
Type: Process
